ABIOGEN PHARMA: THE ITALIAN EXCELLENCE FROM FIVE GENERATIONS

Abiogen Pharma is one of the top 30 pharmaceutical companies in Italy, with over 350 employees and a turnover of about 160 milion € in 2016.

We focus our activities on some therapeutic areas such as: osteoarticular pathologies, pain management, dermatology, pediatric respiratory and diabetes.

In a scenario dominated by the processes of international concentration and integration, a Company strategy geared to change and flexibility is the most valid key to avoid a subordinate role to the globalizing policy of multinational groups. 


Innovation is also the key to flexibility and the pivot on which the Manufacturing activity operates at the state of the art production site opened in Pisa in 2001.


Moreover, Abiogen international expansion is one of the drivers that will support the company’s growth during the next years. Recent partnerships and alliances will allow Abiogen to export more and more “made in Italy” abroad.


Abiogen Pharma applied to the Italian successful model a flexible and innovative approach with a strong vocation for internationalization.


On the other hand It have pursued a strategy to make therapeutic solutions widely accessible, so that all the people can benefit from it.

Go to article: Home | Rise of The Tech GiantsGo to article: The Pharma Industry BriefingGo to article: EditorialGo to article: NSF Go to article: ContentsGo to article: Scandinavian Health Ltd. Company InsightGo to article: Scandinavian Health Ltd.Go to article: NewsGo to article: Fisher Clinical Services Company InsightGo to article: Fisher Clinical ServicesGo to article: DaiichiGo to article: Is China the next great hope for the pharma industry?Go to article: Pfanstiehl Company InsightGo to article: PfanstiehlGo to article: Antimicrobial resistance: is pharmaceutical pollution creating superbugs?Go to article: MedelpharmGo to article: Why is it so hard to reproduce medical research resultsGo to article: Gerteis Company InsightGo to article: GerteisGo to article: Pat-INFORMED: the solution to drug patent procurement issues?Go to article: TSS ABGo to article: Will tech giants like Amazon and Google change the pharma sector forever? Go to article: Capsugel Company InsightGo to article: CapsugelGo to article: Unreal Engine: from gaming to ground-breaking cures Go to article: QualiMetriXGo to article: Are pharma supply chains ready for the next major disruption?Go to article: SensitechGo to article: Can blockchain stem the tide of counterfeit drugs in India? Go to article: Centaur Clinical | Company InsightGo to article: Centaur ClinicalGo to article: EventsGo to article: HOF Sonderanlagenbau Company InsightGo to article: HOF SonderanlagenbauGo to article: Event: Outsourcing in Clinical Trials East Asia Go to article: Wilhelm Haselmeier GmbH & Co KG Company InsightGo to article: Wilhelm Haselmeier GmbH & Co. KGGo to article: Event: Pharmpack EuropeGo to article: Next issueGo to article: PJC Company InsightGo to article: Corbion PuracGo to article: Abiogen PharmaGo to article: BEAGo to article: Unither PharmaceuticalsGo to article: EvolveGo to article: Cargolux Company InsightGo to article: CargoluxGo to article: LaudaGo to article: Dow Europe GmbH Company InsightGo to article: Dow Europe GmbHGo to article: G.F.Go to article: Phoenix Company InsightGo to article: PhoenixGo to article: EcocoolGo to article: B Medical SystemsGo to article: B & W Tek Go to article: Miami International AirportGo to article: PharmasolGo to article: Cryo StoreGo to article: AlpexGo to article: AECO Telecom & Security Systems